BAYN Stock Overview

Operates as a life science company worldwide. More details

BAYN fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 73.9% below our estimate of its fair value

Earnings are forecast to grow 45.63% per year

Earnings have grown 26% per year over the past 5 years

Risk Analysis

Debt is not well covered by operating cash flow

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Bayer Aktiengesellschaft Competitors

Laboratorios RichmondC.I.F

BASE:RICH

AR$119.1b

Galderma Group

SWX:GALD

CHF 23.6b

UCB

ENXTBR:UCB

€31.0b

Royalty Pharma

NasdaqGS:RPRX

US$19.0b

Price History & Performance

Summary of share price highs, lows and changes for Bayer
Historical stock prices
Current Share Price	€3,323.26
52 Week High	€0
52 Week Low	€0
Beta	0.98
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	12,806.01%

Recent updates

Shareholder Returns

	BAYN	AR Pharmaceuticals	AR Market
7D	0%	-3.8%	-1.1%
1Y	n/a	-11.7%	35.2%

Return vs Industry: Insufficient data to determine how BAYN performed against the AR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BAYN performed against the AR Market.

Price Volatility

Is BAYN's price volatile compared to industry and market?
BAYN volatility
BAYN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.8%
10% most volatile stocks in AR Market	10.8%
10% least volatile stocks in AR Market	6.1%

Stable Share Price: BAYN's share price has been volatile over the past 3 months compared to the AR market.

Volatility Over Time: Insufficient data to determine BAYN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1863	90,587	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.

Bayer Aktiengesellschaft Fundamentals Summary

How do Bayer's earnings and revenue compare to its market cap?
BAYN fundamental statistics
Market cap	AR$32.30t
Earnings (TTM)	-AR$3.47t
Revenue (TTM)	AR$63.32t

0.5x

P/S Ratio

-9.3x

P/E Ratio

Is BAYN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BAYN income statement (TTM)
Revenue	€46.61b
Cost of Revenue	€20.20b
Gross Profit	€26.41b
Other Expenses	€28.96b
Earnings	-€2.55b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 13, 2025

Earnings per share (EPS)	-2.60
Gross Margin	56.66%
Net Profit Margin	-5.48%
Debt/Equity Ratio	123.5%

How did BAYN perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

-4%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/06 07:52
End of Day Share Price	2025/02/19 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bayer Aktiengesellschaft is covered by 54 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Martin Schnee	AlphaValue
null null	Banco de Sabadell. S.A.
Emily Field	Barclays